ReviewJournal of thoracic disease2018
The momentum of HeartMate 3: a novel active magnetically levitated centrifugal left ventricular assist device (LVAD).
Review in Journal of thoracic disease, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 43 citations in OpenAlex.
- Functional Status of Patients with Long-Term Mechanical Left Ventricular Assist Device Support in Relation to Physical Activity.Journal of clinical medicine · 2026Article
- Longitudinal assessment of thrombin generation using calibrated automated thrombography in patients with continuous-flow left ventricular assist devices over a five-year period.Scientific reports · 2026Article
- Hemocompatibility and Long-Term Outcomes in HeartWare Versus HeartMate II Versus HeartMate 3: Multicenter Real-World Cohort.Artificial organs · 2026Observational
- Use of LVAD HeartMate 3 and Impella RP in the management of advanced heart failure in an elderly patient: a case report.Indian journal of thoracic and cardiovascular surgery · 2026Article
- Durable left ventricular assist device pump stoppage due to rotor dysfunction.JTCVS techniques · 2025Article
- Review
- The approach to placement of a continuous-flow intracorporeal ventricular assist device in small left ventricle.JHLT open · 2025Article
- A novel cytoprotective organ perfusion platform for reconstructing homeostasis of DCD liver while alleviating IRI injury.Bioengineering & translational medicine · 2025Article
- Beyond Quadruple Therapy and Current Therapeutic Strategies in Heart Failure with Reduced Ejection Fraction: Medical Therapies with Potential to Become Part of the Therapeutic Armamentarium.International journal of molecular sciences · 2024Review
- Hemocompatibility and biophysical interface of left ventricular assist devices and total artificial hearts.Blood · 2024Review
- Pediatric mechanical circulatory support - a review.Indian journal of thoracic and cardiovascular surgery · 2023Review
- Optimal timing of heart transplantation in patients with an implantable left ventricular assist device.Korean journal of transplantation · 2023Review
- Comparison of the Hemocompatibility of an Axial and a Centrifugal Left Ventricular Assist Device in an In Vitro Test Circuit.Journal of clinical medicine · 2022Article
- Article
- Miniaturized soft centrifugal pumps with magnetic levitation for fluid handling.Science advances · 2021Article
- The stunt performed by professional imitation can be dangerous.Indian journal of thoracic and cardiovascular surgery · 2021Article
- Post-operative infection in mechanical circulatory support patients.Annals of translational medicine · 2020Review
- Comparing short-term outcome after implantation of the HeartWare® HVAD® and the Abbott® HeartMate 3®.ESC heart failure · 2020Article
- Current perspectives on mechanical circulatory support.European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery · 2019Review
- The evolution of mechanical circulatory support (MCS): a new wave of developments in MCS and heart failure treatment.Journal of thoracic disease · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Left ventricular assist devices (LVADs) are emerging as the treatment of choice for advanced heart failure due to the dearth of healthy donor hearts for cardiac transplantation. The HeartMate 3 LVAD is a novel centrifugal pump which was developed to provide hemodynamic support in heart failure patients, either as a bridge to transplant (BTT), myocardial recovery, or as destination therapy (DT). Technological and clinical advancements have led to optimized hemocompatibility and development of less invasive surgical procedures for the implantation of this pump. The worldwide first implantation of the HeartMate 3 was performed by Prof. Schmitto and his team at Hannover Medical School, Germany in 2014, paving the way for subsequent surgical developments. This article summarizes the advanced technological and clinical aspects of the HeartMate 3 and outlines future technical developments for safe and effective treatment of advanced heart failure.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.